Looking for high-purity bronchogen gas exchange for sale for laboratory research? PX1 Research provides analytical-grade Bronchogen (Ala-Glu-Asp-Leu) synthesized to >98% purity, validated by third-party HPLC and Mass Spectrometry for preclinical investigation into pulmonary epithelial dynamics and alveolar gas exchange mechanics. Every batch is manufactured in the USA, endotoxin-tested, and accompanied by a lot-specific Certificate of Analysis.
Looking for high-purity bronchogen gas exchange for sale for laboratory research? PX1 Research provides analytical-grade Bronchogen (Ala-Glu-Asp-Leu) synthesized to >98% purity, validated by third-party HPLC and Mass Spectrometry for preclinical investigation into pulmonary epithelial dynamics and alveolar gas exchange mechanics. Every batch is manufactured in the USA, endotoxin-tested, and accompanied by a lot-specific Certificate of Analysis.
Bronchogen is a synthetic short-chain peptide bioregulator comprised of the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Categorized within the broad family of peptide bioregulators, Bronchogen was developed to mimic specific regulatory fragments derived from bronchial tissue extracts. In preclinical research settings, scientists utilize Bronchogen to investigate direct genomic and non-genomic interactions within respiratory epithelial cells and pulmonary stromal tissues.
When evaluating options to source bronchogen gas exchange for sale, investigators require clear documentation of molecular identity and chemical purity. Bronchogen has a precise molecular weight of approximately 460.45 g/mol and exhibits high solubility in aqueous buffer systems commonly utilized in tissue culture work. As a short tetrapeptide, its compact tertiary structure allows for distinct cellular permeability profiles in *in vitro* models compared to larger structural proteins or whole tissue homogenates.
Primary research applications focus on the compound's capacity to modulate cellular proliferation, apoptosis, and functional protein synthesis in bronchial cell lines. Investigators accessing our comprehensive research hub can review analytical specifications and biochemical properties associated with short-chain peptide bioregulators across diverse organ system models.
The primary interest surrounding Bronchogen in pulmonary research stems from its observed effects on the alveolar-capillary membrane and bronchial epithelium. In preclinical models, optimal gas exchange across the pulmonary membrane relies upon intact tight junctions, balanced surfactant production, and low baseline inflammation within the respiratory parenchyma.
*In vitro* assays utilizing human bronchial epithelial cell lines demonstrate that Bronchogen exposure modulates the transcription of key structural and functional proteins. Preclinical studies suggest that the peptide can cross nuclear membranes in cultured cells, binding directly to specific histone proteins and DNA promoter regions. This epigenetic interaction is hypothesized to upregulate genes associated with surfactant proteins (such as SP-A and SP-B) while downregulating pro-inflammatory cytokine expression following toxicant or oxidative challenges.
Furthermore, animal models evaluating pulmonary function under stress conditions indicate that Bronchogen administration may help preserve microvascular integrity within the lung parenchyma. By supporting the structural homeostasis of type I and type II pneumocytes, the peptide provides a valuable molecular tool for studying gas diffusion capacity, lung compliance, and barrier repair mechanisms following simulated tissue injury.
Preclinical literature documenting Bronchogen's biological activity spans both cell-free assays and complex *in vivo* animal models. Early tissue culture studies established that low micromolar concentrations of Bronchogen influence chromatin accessibility in senescent or stressed bronchial fibroblasts, restoring transcription rates of structural matrix components to baseline levels observed in juvenile cell populations.
In rodent models of induced acute respiratory distress and chronic pulmonary inflammation, researchers observed that treatment with Bronchogen reduced neutrophilic infiltration into bronchoalveolar lavage fluid (BALF). Concurrently, measurements of partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) in arterial blood samples revealed improved gas exchange efficacy in peptide-treated cohorts compared to vehicle controls.
Additional laboratory assays focusing on antioxidant enzyme activity have demonstrated that Bronchogen exposure correlates with increased expression of superoxide dismutase (SOD) and catalase in lung homogenates. These findings suggest a dual protective mechanism: direct nuclear signaling leading to cellular regeneration, coupled with enhanced intrinsic resistance to reactive oxygen species generated during hypoxia or toxin exposure.
When designing comparative preclinical trials involving short-chain peptide bioregulators, researchers frequently evaluate Bronchogen alongside other tissue-specific or system-wide regulatory peptides. Understanding the functional divergence between these sequences is critical for selecting the appropriate compound for specific cellular assays.
While Bronchogen specifically targets pulmonary epithelial tissue and gas exchange parameters, related synthetic bioregulators demonstrate distinct organ affinities. For instance, Cartalax (Ala-Glu-Asp-Pro) is primarily studied for its regulatory effects on chondrocyte differentiation and extracellular matrix synthesis in articular cartilage models. Similarly, Vilon (Lys-Glu) is utilized to evaluate T-cell activation and thymic epithelial signaling, whereas Epitalon (Ala-Glu-Asp-Gly) is widely investigated for telomerase induction and pineal gland regulation across systemic aging models.
The table below highlights key structural and functional distinctions among these short peptide bioregulators available in our catalog of all peptides:
To ensure reproducible experimental outcomes, research peptides must conform to stringent analytical quality control protocols. PX1 Research enforces rigorous verification procedures for every lot of Bronchogen synthesized, ensuring that investigators receive reference-grade materials free from chemical artifacts or biological contaminants.
Purity is assessed primarily via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). This process separates the target tetrapeptide from potential synthesis bypass products or deletion sequences, verifying a chemical purity threshold of equal to or greater than 98.0%. Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or Liquid Chromatography-Mass Spectrometry (LC-MS) is performed simultaneously to confirm the exact molecular mass and amino acid sequence identity.
Because Bronchogen is frequently investigated in cellular models sensitive to lipopolysaccharides (LPS), endotoxin control is paramount. Substandard peptides containing bacterial endotoxins can confound immunological and gas exchange assays by triggering non-specific inflammatory cascades. PX1 Research subjects all peptide lots to Chromogenic Reagent Limulus Amebocyte Lysate (LAL) testing, guaranteeing endotoxin levels below 0.05 EU/mg. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, and quantitative endotoxin data.
Proper handling and storage procedures are essential to maintain the structural integrity of synthetic Bronchogen over the duration of an experimental protocol. Lyophilized Bronchogen is stable at ambient temperatures during short-term transport, but should be stored at -20°C or -80°C upon arrival for long-term preservation.
When reconstituting Bronchogen for *in vitro* or preclinical application, researchers should observe strict aseptic techniques within a laminar flow hood. The lyophilized cake rapidly dissolves in sterile, deionized water, phosphate-buffered saline (PBS, pH 7.4), or standard cell culture media. For long-term liquid storage, aliquoting the reconstituted solution into single-use polypropylene tubes is strongly recommended to avoid repeated freeze-thaw cycles, which can induce peptide degradation.
Working stock solutions maintained at 4°C should typically be utilized within 7 to 14 days, provided sterile handling procedures are maintained. For detailed buffer compatibility guides and reconstitution calculations, researchers can access technical resources through our wholesale and lab account setup.
In designing *in vitro* assays to evaluate pulmonary gas exchange markers, researchers typically test Bronchogen across a concentration gradient ranging from 10 nM to 10 µM. Cultured human bronchial epithelial cells (e.g., BEAS-2B or Primary NHBE cells) are treated for defined time points (24 to 72 hours) prior to measuring downstream markers such as transepithelial electrical resistance (TEER) and surfactant protein transcription.
In animal model frameworks, administration protocols depend significantly on the disease or injury model being investigated (e.g., hyperoxia exposure, bleomycin-induced fibrosis, or lipopolysaccharide-induced acute lung injury). Control groups receiving vehicle-only buffers are necessary to differentiate specific peptide-mediated epigenetic responses from baseline cellular repair.
It is imperative to note that all operational parameters, concentration ranges, and delivery methods discussed in the literature pertain strictly to non-human animal models and cell culture systems. Bronchogen is supplied exclusively for laboratory research purposes.
PX1 Research is committed to supplying the scientific community with USA-manufactured research peptides manufactured under strict quality management systems. By adhering to ISO 17025 laboratory standards and GMP-compliant manufacturing practices, we ensure that every vial of Bronchogen meets the exacting demands of academic, pharmaceutical, and institutional researchers.
Our supply chain features complete lot traceability, transparent third-party testing, and same-day dispatch from our centralized logistics centers in California and Arizona (for orders placed Monday through Friday before cut-off times). Whether conducting exploratory cell culture screens or large-scale preclinical studies requiring custom synthesis scales available through our wholesale account portal, PX1 Research delivers reliable, verified research compounds to advance pulmonary science.
What is Bronchogen and what is its chemical sequence?
Bronchogen is a short synthetic peptide bioregulator consisting of four amino acids: L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). It was designed to mimic the active peptide fragments isolated from bronchial tissue.
What primary research applications involve Bronchogen?
Bronchogen is studied in preclinical research to investigate pulmonary epithelial barrier function, surfactant production dynamics, cellular regeneration in bronchial tissue, and gas exchange efficiency in laboratory models.
How does PX1 Research verify the purity of Bronchogen?
Every lot of Bronchogen undergoes third-party analytical testing utilizing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity (≥98%) and Mass Spectrometry (MS) to verify precise molecular weight and identity.
What are the endotoxin thresholds for PX1 Research Bronchogen?
PX1 Research verifies that all Bronchogen batches pass Limulus Amebocyte Lysate (LAL) testing with endotoxin levels strictly below 0.05 EU/mg, making it suitable for sensitive cell culture and animal tissue models.
How should lyophilized Bronchogen be stored upon receipt?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry environment protected from light. Under these conditions, the powder remains stable for extended periods.
What solvents are recommended for reconstituting Bronchogen in a lab setting?
Bronchogen readily dissolves in sterile bacteriostatic water, sterile normal saline (0.9% NaCl), or phosphate-buffered saline (PBS, pH 7.4). Avoid aggressive vortexing to prevent mechanical shear.
Is Bronchogen approved for human clinical use or medical treatment?
No. Bronchogen provided by PX1 Research is sold strictly for in vitro, laboratory, and preclinical research applications. It is not approved for human or animal therapeutic, diagnostic, or clinical use.
Can institution researchers purchase Bronchogen in bulk quantities?
Yes. Qualified academic and corporate laboratories can place bulk orders or establish institutional supply accounts via our wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.